Quantum precision reached in modeling molten salt behavior
Energy Secretary Jennifer Granholm visited ORNL on Nov. 22 for a two-hour tour, meeting top scientists and engineers as they highlighted projects and world-leading capabilities that address some of the country’s most complex research and technical challenges.
As a medical isotope, thorium-228 has a lot of potential — and Oak Ridge National Laboratory produces a lot.
Four first-of-a-kind 3D-printed fuel assembly brackets, produced at the Department of Energy’s Manufacturing Demonstration Facility at Oak Ridge National Laboratory, have been installed and are now under routine operating
Scientists at ORNL and the University of Wisconsin–Madison have discovered that genetically distinct populations within the same species of fungi can produce unique mixes of secondary metabolites, which are organic compounds with applications in
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.
At the Department of Energy’s Oak Ridge National Laboratory, scientists use artificial intelligence, or AI, to accelerate the discovery and development of materials for energy and information technologies.
Belinda Akpa is a chemical engineer with a talent for tackling big challenges and fostering inclusivity and diversity in the next generation of scientists.
Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.
When COVID-19 was declared a pandemic in March 2020, Oak Ridge National Laboratory’s Parans Paranthaman suddenly found himself working from home like millions of others.
The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.